Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal

Vasco Quaresma; Lorenzo Marconi; Roberto Jarimba; João Lima; Arnaldo Figueiredo

doi:10.20344/amp.18837

Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal

Authors

Vasco Quaresma Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra. https://orcid.org/0000-0001-9225-1437
Lorenzo Marconi Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra; Faculty of Medicine. University of Coimbra. Coimbra.
Roberto Jarimba Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra.
João Lima Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra.
Arnaldo Figueiredo Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra; Faculty of Medicine. University of Coimbra. Coimbra.

DOI:

https://doi.org/10.20344/amp.18837

Keywords:

Carcinoma, Transitional Cell, Immunotherapy, Urinary Bladder Neoplasms/drug therapy

Abstract

N/a.

Downloads

Download data is not yet available.

References

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: longterm results in 1,054 patients. J Clin Oncol. 2001;19:666-75. DOI: https://doi.org/10.1200/JCO.2001.19.3.666

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34. DOI: https://doi.org/10.1016/j.urology.2005.07.062

Galsky MD, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211-4. DOI: https://doi.org/10.1016/S1470-2045(10)70275-8

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fonf L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-26. DOI: https://doi.org/10.1056/NEJMoa1613683

Hoffman-Censits JH, Grivas P, Van Der Heijden MS, Van-Der-Heijden M, Dreicer R, Loriot Y, et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol. 2016;34:355. DOI: https://doi.org/10.1200/jco.2016.34.2_suppl.355

Downloads

Published

2023-02-01

How to Cite

Quaresma V, Marconi L, Jarimba R, Lima J, Figueiredo A. Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal. Acta Med Port [Internet]. 2023 Feb. 1 [cited 2024 Nov. 23];36(2):145-6. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/18837

Download Citation

Issue

Vol. 36 No. 2 (2023): February

Section

Letters to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.